Search research articles
Contact Us
Filters
Showing results (61-70 of 220) with videos related to
Page
of 22
Sort By:
Advances in Neurology
|
January 1, 1996
Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences
J L Montastruc, J M Senard, O Rascol, et al.
Clinical Neuropharmacology
|
January 1, 1986
Mesulergine (CU 32-085) in the treatment of Parkinson's disease
A Rascol, J L Montastruc, O Rascol, et al.
Lancet (London, England)
|
April 25, 2000
Sleep attacks and Parkinson's disease treatment
J J Ferreira, M Galitzky, J L Montastruc, et al.
The Journal of Nutrition, Health & Aging
|
March 24, 2006
Disease modifying trials in Alzheimer disease: methodological and statistical issues
S Andrieu, O Rascol, T Lang, et al.
European Journal of Neurology
|
March 22, 2008
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight
J C Sharma, I N Ross, O Rascol, et al.
Neuroscience
|
June 1, 1992
Alterations in the properties of hippocampal pyramidal neurons in the aged rat
B Potier, O Rascol, F Jazat, et al.
Advances in Neurology
|
July 20, 1999
Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients
O Rascol, C Brefel-Courbon, S Descombes, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
June 1, 1995
Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians
J M Sénard, P Verwaerde, O Rascol, et al.
Therapie
|
September 12, 1998
[Central dopaminergic D1 agonists and treatment of Parkinson disease]
C Soubrouillard, C Lombardo, O Rascol, et al.
Therapie
|
September 1, 1995
[Movement disorders induced by drugs: experience at a pharmaco-vigilance center over five years]
M E Llau, J M Senard, O Rascol, et al.
Page
of 22
Search research articles
Search
Showing results (61-70 of 220) with videos related to
Sort By:
Page
of 22
Advances in Neurology
|
January 1, 1996
Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences
J L Montastruc, J M Senard, O Rascol, et al.
Clinical Neuropharmacology
|
January 1, 1986
Mesulergine (CU 32-085) in the treatment of Parkinson's disease
A Rascol, J L Montastruc, O Rascol, et al.
Lancet (London, England)
|
April 25, 2000
Sleep attacks and Parkinson's disease treatment
J J Ferreira, M Galitzky, J L Montastruc, et al.
The Journal of Nutrition, Health & Aging
|
March 24, 2006
Disease modifying trials in Alzheimer disease: methodological and statistical issues
S Andrieu, O Rascol, T Lang, et al.
European Journal of Neurology
|
March 22, 2008
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight
J C Sharma, I N Ross, O Rascol, et al.
Neuroscience
|
June 1, 1992
Alterations in the properties of hippocampal pyramidal neurons in the aged rat
B Potier, O Rascol, F Jazat, et al.
Advances in Neurology
|
July 20, 1999
Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients
O Rascol, C Brefel-Courbon, S Descombes, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension
|
June 1, 1995
Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians
J M Sénard, P Verwaerde, O Rascol, et al.
Therapie
|
September 12, 1998
[Central dopaminergic D1 agonists and treatment of Parkinson disease]
C Soubrouillard, C Lombardo, O Rascol, et al.
Therapie
|
September 1, 1995
[Movement disorders induced by drugs: experience at a pharmaco-vigilance center over five years]
M E Llau, J M Senard, O Rascol, et al.
Page
of 22